Immunological off-target effects of imatinib (Q34046541)

30 July 2017

Immunological off-target effects of imatinib (English)

1 reference

30 July 2017

1 reference

1 reference

1

0 references

Sylvie Rusakiewicz

series ordinal

2

object named as

Sylvie Rusakiewicz

0 references

Guido Kroemer

series ordinal

5

object named as

Guido Kroemer

0 references

Bertrand Routy

series ordinal

3

object named as

Bertrand Routy

1 reference

30 July 2017

4

Maha Ayyoub

1 reference

PubMed ID

27030078

30 July 2017

language of work or name

English

0 references

publication date

31 March 2016

1 reference

Nature Reviews Clinical Oncology

30 July 2017

1 reference

30 July 2017

13

1 reference

30 July 2017

431-446

1 reference

30 July 2017

7

1 reference

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

30 July 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

31 March 2020

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Commensal bacteria calibrate the activation threshold of innate antiviral immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Refining the treatment of NSCLC according to histological and molecular subtypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

The evolving war on cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Trial Watch: Chemotherapy with immunogenic cell death inducers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Combining immunotherapy and targeted therapies in cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Kit regulates maintenance of quiescent hematopoietic stem cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Abl family tyrosine kinases regulate sialylated ganglioside receptors for polyomavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

The Abl and Arg kinases mediate distinct modes of phagocytosis and are required for maximal Leishmania infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

KIT oncogene inhibition drives intratumoral macrophage M2 polarization.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Dendritic cell c-kit signaling and adaptive immunity: implications for the upper airways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Development and dynamics of robust T-cell responses to CML under imatinib treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Defects in DBA: more than meets the eye.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Minor histocompatibility antigens: past, present, and future.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Identification of minor histocompatibility antigens based on the 1000 Genomes Project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Frequent expression of HAGE in presentation chronic myeloid leukaemias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

BAG-6, a jack of all trades in health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

A soluble fragment of the tumor antigen BCL2-associated athanogene 6 (BAG-6) is essential and sufficient for inhibition of NKp30 receptor-dependent cytotoxicity of natural killer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

New insights into antigen specific immunotherapy for chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Cancer testis antigen expression in gastrointestinal stromal tumors: new markers for early recurrence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Exploiting antitumor immunity to overcome relapse and improve remission duration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

A novel dendritic cell subset involved in tumor immunosurveillance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

IKDCs or B220+ NK cells are pre-mNK cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Redefining interferon-producing killer dendritic cells as a novel intermediate in NK-cell differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

The dendritic cell-like functions of IFN-producing killer dendritic cells reside in the CD11b+ subset and are licensed by tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Migratory and antigen presentation functions of IFN-producing killer dendritic cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Novel monogenic diseases causing human autoimmunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Immune checkpoint blockade: a common denominator approach to cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Trabectedin: A drug from the sea that strikes tumor-associated macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Leukocyte protein tyrosine kinases: potential targets for drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Abl tyrosine kinases in T-cell signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

A small molecule-kinase interaction map for clinical kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Lck is a key target of imatinib and dasatinib in T-cell activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Immunogenic cell death in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Autophagy and cellular immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

A dual role for autophagy in a murine model of lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Immunogenic and tolerogenic cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

CD8+ memory T cells predominate over naïve T cells in therapy-free CML patients with sustained major molecular response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.41

In vivo administration of stem cell factor to mice increases the absolute number of pluripotent hematopoietic stem cells.

31 March 2020

1 reference

12 December 2020

The molecular biology of chronic myeloid leukemia.

1 reference

12 December 2020

Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects

1 reference

12 December 2020

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

1 reference

12 December 2020

Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors.

1 reference

12 December 2020

T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation

1 reference

12 December 2020

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells

1 reference

12 December 2020

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

1 reference

12 December 2020

Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.

1 reference

12 December 2020

Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.

1 reference

12 December 2020

CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells.

1 reference

12 December 2020

10.1038/NRCLINONC.2016.41

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

27030078